Clot Lysis in a Primate Model of Peripheral Arterial Occlusive Disease with Use of Systemic or Intraarterial Reteplase: Addition of Abciximab Results in Improved Vessel Reperfusion

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 2 I, 2004, Pages 169-176

  Nakada, Marian T ^a   Montgomery, Michael O ^a   Nedelman, Mark A ^b   Guerrero, J Luis ^b   Cohen, Sidney A ^a   Barnathan, Elliot S ^a   Jordan, Robert E ^a  

^a CENTOCOR INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; RETEPLASE; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD CLOT LYSIS; CONTROLLED STUDY; FIBRINOLYSIS; MONKEY; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RECANALIZATION; REPERFUSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

EID: 1342282930     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000109395.74740.1F     Document Type: Article

References (33)

1. Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998; 97:211-221.
2. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE. The heart and cardiovascular system, second edition. New York: Raven Press, 1992;219-273.
3. Moliterno DJ, Topol EJ. Conjunctive use of platelet glycoprotein IIb/ IIIa antagonists and thrombolytic therapy for acute myocardial infarction. Thromb Haemost 1997; 78:214-219.
4. Martin U. Clinical and preclinical profile of the novel recombinant plasminogen activator reteplase. In: Sasahar AA, Loscalzo J, eds. New therapeutic agents in thrombosis and thrombolysis. New York: Marcel Dekker, 1997;495-511.
5. Collen D, Topol EJ, Teifenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984; 70:1012-1017.
6. Verstraete M. Third-generation thrombolytic drugs. Am J Med 2000; 109:52.
7. Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis Proteolysis 1997; 11:129-135.
8. Lincoff AM, Califf RMJ, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1997; 30:149-156.
9. Topol EJ, Byzova TV, Plow EF. Platelet GpIIb-IIIa blockers. Lancet 1999; 353:227-231.
10. Kohmura C, Gold HK, Yasuda T, et al. A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons. Arterioscler Thromb 1993; 13:1837-1842.
11. Jordan RE, Wagner CL, Mascelli MA, et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion receptors as therapeutic targets. Boca Raton, FL: CRC Press, 1996;281-305.
12. Coller BS, Folts JD, Smith SR, Scudder LE, Jordan R. Abolition of in vivo thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80:1766-1774.
13. Davidian MM, Powell A, Benenati JF, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11:289-294.
14. Coller BS. Augmentation of thrombolysis with antiplatelet drugs: overview. Coron Artery Dis 1995; 6:911-914.
15. vβ3 integrins. Circulation 1998; 98:1085-1091.
16. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98:863-874.
17. Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101:2788-2794.
18. Antman EM, Gibson CM, de Lemos JA, et al, for the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J 2000; 21:1944-1953.
19. Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695-2701.
20. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion-a consensus document. Am J Cardiol 1998; 81:207-218.
21. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:848-854.
22. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996; 94:891-898.
23. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:849-854.
24. Castaneda F, Swischuk JL, Li R, Young K, Smouse B, Brady T. Declining-dose study of reteplase treatment for lower extremity arterial occlusions. J Vasc Interv Radiol 2002; 13:1093-1098.
25. Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady T. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. J Vasc Interv Radiol 2002; 13:577-580.
26. Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am Heart J 2000; 139:696-703.
27. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1904-1914.
28. Jordan RE, Nakada MT, Weisman HF. Abciximab: the first platelet glycoprotein IIb/IIIa receptor antagonist. In: Walsh G, Murphy B, eds. Biopharmaceuticals: an industrial perspective. Boston: Kluwer, 1999;35-71.
29. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90:1757-1764.
30. Schweizer J, Kirch W, Koch R, Muller A, Hellner G, Forkmann L. Short and long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000; 51:913-923.
31. Duda S, Tepe G, Luz O, et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone: a randomized pilot trial (the PROMPT Study). Radiology 2000; 221:689-696.
32. Drescher P, McGuckin J, Rilling WS, Crain MR. Catheter-directed thrombolytic therapy in peripheral artery occlusions: combining reteplase and abciximab. AJR Am J Roentgenol 2003; 180:1385-1391.
33. McNamara TO, Aban KT, Quinn B, Chen JL. Combination of ReoPro and Retavase in thrombolysis of peripheral arterial occlusions: preliminary results vascular intervention [abstract]. J Vasc Interv Radiol 2001; 12(suppl):S123.